Investors piled into Merck & Co. and S & P Global , among others, with 2026 around the corner. Those names may be due for a pullback. The three major averages all climbed this week, which was shortened because of the Christmas holiday. The S & P 500 led the way with a 1.4% gain. The Nasdaq Composite was up 1.2% along with the Dow Jones Industrial Average . However, some individual stocks may be over their skis and due for a retracement. CNBC Pro used its stock screener tool to identify the most overbought and oversold stocks on Wall Street as measured by their 14-day relative strength index, or RSI. Stocks with a 14-day RSI above 70 are said to be overbought, meaning that they could be soon due for a potential rebound. On the other hand, a reading below 30 indicates that a stock is oversold and that a rebound could be on the horizon. The table below shows stocks with an RSI above 70 that also rose at least 3% for the week, as of Friday morning. With an RSI of 73, one standout name on the list was Merck. Shares of the pharmaceutical giant were up 5% on the week. Last week, BMO Capital Markets upgraded the stock to an outperform rating. “Following a course reversal for Merck sentiment, driven by stabilizing Gardasil estimates, recent U.S. government agreements, and positive trials like CADENCE, we believe investors see more upside to MRK in the near term,” wrote analyst Evan Seigerman. “While not all questions have been answered to replace Keytruda revenue, we see a credible path to solve most of the picture with upside still attainable regardless of mild [earnings per share] contraction through the [loss of exclusivity].” S & P Global, up 3% this week and with an RSI of 72, was another name on the most overbought list. Morgan Stanley named the stop one of its top picks in a 2026 outlook, published last week. “SPGI has already de-risked following its Investor Day in November where the company provided growth and margin targets that were within the levels of prior expectations,” wrote analyst Toni Kaplan. On the other hand, there were some names that entered oversold territory, signaling they may be due for a jump. The table below shows stocks with an RSI below 30 that have also slipped at least 1% week to date, as of Friday morning. Coming in with an RSI of 28, Lennar fell 3% this week. Last week, several Wall Street shops downgraded the homebuilder to an underperform rating, including Bank of America, Evercore ISI and RBC Capital Markets. Bank of America analyst Rafe Jadrosich said that his downgrade came after Lennar issued fourth-quarter results and first-quarter guidance that came in well below expectations. “We are reducing our FY2026/FY2027 EPS estimates by (24%)/(14%) to reflect a weaker margin and revenue outlook,” he wrote. “LEN shares declined (5%) versus (1%) for the S & P 500, and we see further downside risk as the stock continues to trade at a premium despite lower ROTE and more pronounced margin and return-on-equity headwinds relative to peers.” Lamb Weston, DataDog and Marathon Petroleum rounded out the list of oversold stocks.
Friday, February 13
These are the most overbought S&P 500 stocks as 2026 approaches
Risk Disclosure and Disclaimer for PropFirmFinance.com
Trading financial instruments, including forex, stocks, commodities, and cryptocurrencies, involves a high level of risk and may not be suitable for all investors. The value of financial instruments can fluctuate significantly due to market volatility, economic events, regulatory actions, or political developments. You may sustain a loss of some or all of your invested capital. Trading on margin or using leverage can further amplify losses and increase your financial exposure.
Before engaging in any trading activity, carefully assess your investment goals, level of experience, and risk appetite. It is strongly recommended to seek advice from a licensed financial advisor if you are uncertain about the risks involved.
PropFirmFinance.com provides content for informational and educational purposes only. While we strive to offer accurate, timely, and up-to-date information, we do not guarantee the accuracy, completeness, or reliability of any data presented on this website. Market data, prices, charts, and signals may not always be real-time or sourced from official exchanges. Such information is provided on an “as-is” basis and should not be used for trading or investment decisions.
PropFirmFinance.com, its owners, contributors, and partners shall not be held responsible for any losses or damages incurred as a result of using the information provided on this website. Users assume full responsibility for their trading actions and outcomes.
All content on this site, including data, text, graphics, and logos, is protected by applicable intellectual property laws. Any reproduction, redistribution, or unauthorized use of material from this website is strictly prohibited without prior written consent.
We may receive compensation from partners and advertisers featured on this website. Compensation may influence the placement or visibility of certain content but does not affect our editorial integrity or objectivity.
By using this website, you acknowledge and agree to the terms of this disclaimer.
© 2026 propfirmfinance.com.